(Q46547178)

23 December 2017

title

Effects of Fatty Acid Synthase Inhibition by Orlistat on Proliferation of Endometrial Cancer Cell Lines (English)

1 reference

23 December 2017

0 references

1 reference

Weiya Z Wysham

1

1 reference

23 December 2017

Dario R Roque

2

1 reference

23 December 2017

Jianjun Han

3

1 reference

23 December 2017

Lu Zhang

4

1 reference

23 December 2017

Hui Guo

5

1 reference

23 December 2017

Paola A Gehrig

6

1 reference

23 December 2017

Chunxiao Zhou

7

1 reference

23 December 2017

Victoria L Bae-Jump

8

1 reference

23 December 2017

publication date

18 May 2016

1 reference

23 December 2017

published in

Targeted oncology

1 reference

23 December 2017

volume

11

1 reference

23 December 2017

issue

6

1 reference

23 December 2017

page(s)

763-769

1 reference

23 December 2017

https://scigraph.springernature.com/pub.10.1007/s11523-016-0442-9

exact match

0 references

cites work

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Factors associated with Type I and Type II endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Orlistat, a new lipase inhibitor for the management of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Mechanism of Orlistat Hydrolysis by the Thioesterase of Human Fatty Acid Synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Fatty acid synthase: a metabolic oncogene in prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Fatty acid synthase as a potential therapeutic target in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Fatty acid synthase is a potential therapeutic target in estrogen receptor-/progesterone receptor-positive endometrioid endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Targeting fatty acid synthase in breast and endometrial cancer: An alternative to selective estrogen receptor modulators?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Fatty acid synthase is a key target in multiple essential tumor functions of prostate cancer: uptake of radiolabeled acetate as a predictor of the targeted therapy outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Obesity induced rapid melanoma progression is reversed by orlistat treatment and dietary intervention: role of adipokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Fatty acid synthase inhibition with Orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Tumor growth retardation and chemosensitizing action of fatty acid synthase inhibitor orlistat on T cell lymphoma: implication of reconstituted tumor microenvironment and multidrug resistance phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Lipid catabolism via CPT1 as a therapeutic target for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Targeting AMPK: a new therapeutic opportunity in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Therapeutic targeting of the mTOR-signalling pathway in cancer: benefits and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Antitumor effect of orlistat, a fatty acid synthase inhibitor, is via activation of caspase-3 on human colorectal carcinoma-bearing animal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Role of AMP-activated protein kinase in mechanism of metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Folate Receptor-Targeted Polymeric Micellar Nanocarriers for Delivery of Orlistat as a Repurposed Drug against Triple-Negative Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Orlistat and antisense-miRNA-loaded PLGA-PEG nanoparticles for enhanced triple negative breast cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis/prognosis marker.

21 January 2018

1 reference

12 December 2020

Fatty acid synthesis is a therapeutic target in human liposarcoma

1 reference

12 December 2020

The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells

1 reference

12 December 2020

Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells.

1 reference

12 December 2020

The impact of obesity and age on quality of life in gynecologic surgery

1 reference

12 December 2020

Fatty acid synthase expression and clinicopathological findings in endometrial cancer

1 reference

12 December 2020

Fatty acid synthase inhibitor orlistat induces apoptosis in T cell lymphoma: role of cell survival regulatory molecules

1 reference

12 December 2020

Fatty acid synthase inhibition engages a novel caspase-2 regulatory mechanism to induce ovarian cancer cell death.

1 reference

12 December 2020

10.1007/S11523-016-0442-9

Identifiers

DOI

1 reference

23 December 2017

PubMed ID

27188391

1 reference

23 December 2017